journal article·2023-07-20Open access

Combined System for the Simultaneous Delivery of Levofloxacin and Rifampicin: Structural and Functional Properties and Antibacterial Activity

Irina M. Le-Deygen, Polina V. Mamaeva, Anna A. Skuredina, Anastasia S. Safronova, Natalia G. Belogurova, Elena V. Kudryashova

Abstract

The therapy of resistant forms of tuberculosis requires the simultaneous use of several drugs, in particular, a combination of rifampicin and levofloxacin. In this paper, we aimed to design a combined system for the simultaneous delivery of these drugs for potential inhalation administration. A feature of this system is the incorporation of rifampicin into optimized liposomal vesicles capable of forming a multipoint non-covalent complex with chitosan-β-cyclodextrin conjugates. Levofloxacin is incorporated into cyclodextrin tori by forming a host–guest complex. Here, a comprehensive study of the physicochemical properties of the obtained systems was carried out and special attention was paid to the kinetics of cargo release for individual drugs and in the combined system. The release of levofloxacin in combined system is slow and is described by the Higuchi model in all cases. The release of rifampicin from liposomes during the formation of complexes with polymeric conjugates is characterized by the change of the Higuchi model to the Korsmeyer–Peppas model with the main type of diffusion against Fick′s law. Microbiological studies in solid and liquid growth media a consistently high antibacterial activity of the obtained systems was shown against B. subtilis and E. coli.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia

Funding

President of Russia grant for young PhDs

References (43)

Show source-provided references
1. Impact of HIV infection on tuberculosis10.1136/pmj.76.895.259 ↗
2. TB and COVID-19: An Exploration of the characteristics and resulting complications of co-infection10.31083/j.fbs1401006 ↗
3. Advancing the development of tuberculosis therapy10.1038/nrd3694 ↗
4. Evolution of rifampicin treatment for tuberculosis10.1016/j.meegid.2019.103937 ↗
5. Resistance to rifampicin: At the crossroads between ecological, genomic and medical concerns10.1016/j.ijantimicag.2009.12.017 ↗
6. A Note on Derivatives of isoniazid, rifampicin, and pyrazinamide showing activity against resistant Mycobacterium tuberculosis10.1111/cbdd.12684 ↗
7. The role of fluoroquinolones in tuberculosis today10.2165/00003495-200161010-00002 ↗
8. Activity of quinolones against mycobacteria10.2165/00003495-199958002-00004 ↗
9. Levofloxacin review of its antibacterial activity, pharmacokinetics and therapeutic efficacy10.2165/00003495-199447040-00008 ↗
10. Pulmonary drug delivery systems for tuberculosis treatment10.1016/j.ijpharm.2014.12.009 ↗
11. Composition influence on pulmonary delivery of rifampicin liposomes10.3390/pharmaceutics4040590 ↗
12. Drug–membrane interaction as revealed by spectroscopic methods: The role of drug structure in the example of rifampicin, levofloxacin and rapamycin10.3390/biophysica2040032 ↗
13. Forte, J., Hanieh, P.N., Poerio, N., Olimpieri, T., Ammendolia, M.G., Fraziano, M., Fabiano, M.G., Marianecci, C., Carafa, M., and Bordi, F. (2023). Mucoadhesive rifampicin-liposomes for the treatment of pulmonary infection by Mycobacterium abscessus: Chitosan or ε-Poly-L-Lysine decoration. Biomolecules, 13.10.3390/biom13060924 ↗
14. Garcia-Contreras, L., Sethuraman, V., Kazantseva, M., and Hickey, A. (2021). Efficacy of combined rifampicin formulations delivered by the pulmonary route to treat tuberculosis in the guinea pig model. Pharmaceutics, 13.10.3390/pharmaceutics13081309 ↗
15. Le-Deygen, I.M., Skuredina, A.A., Mamaeva, P.V., Kolmogorov, I.M., and Kudryashova, E.V. (2023). Conjugates of chitosan with β-Cyclodextrins as promising carriers for the delivery of levofloxacin: Spectral and microbiological studies. Life, 13.10.3390/life13020272 ↗
16. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system10.1016/j.ijpharm.2007.03.005 ↗
17. Chitosan/cyclodextrin nanoparticles as drug delivery system10.1007/s10847-011-9950-5 ↗
18. Cyclodextrin/chitosan nanoparticles for oral ovalbumin delivery: Preparation, characterization and intestinal mucosal immunity in mice10.1016/j.ajps.2018.04.001 ↗
19. Biocompatibility study of theophylline/chitosan/β-cyclodextrin microspheres as pulmonary delivery carriers10.1007/s10856-008-3680-2 ↗
20. De Gaetano, F., Marino, A., Marchetta, A., Bongiorno, C., Zagami, R., Cristiano, M.C., Paolino, D., Pistarà, V., and Ventura, C.A. (2021). Development of chitosan/cyclodextrin nanospheres for levofloxacin ocular delivery. Pharmaceutics, 13.10.3390/pharmaceutics13081293 ↗
21. Chopra, H., Mohanta, Y.K., Rauta, P.R., Ahmed, R., Mahanta, S., Mishra, P.K., Panda, P., Rabaan, A.A., Alshehri, A.A., and Othman, B. (2023). An insight into advances in developing nanotechnology based therapeutics, drug delivery, diagnostics and vaccines: Multidimensional applications in tuberculosis disease management. Pharmaceuticals, 16.10.3390/ph16040581 ↗
22. Stability indicating HPLC method for the simultaneous determination of moxifloxacin and prednisolone in pharmaceutical formulations10.1186/1752-153X-6-94 ↗
23. Methods for in vitro evaluating antimicrobial activity: A review10.1016/j.jpha.2015.11.005 ↗
24. Skuredina, A.A., Tychinina, A.S., Le-Deygen, I.M., Golyshev, S.A., Kopnova, T.Y., Le, N.T., Belogurova, N.G., and Kudryashova, E.V. (2022). Cyclodextrins and their polymers affect the lipid membrane permeability and increase levofloxacin’s antibacterial activity in vitro. Polymers, 14.10.3390/polym14214476 ↗
25. Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine10.1016/j.ijbiomac.2019.11.190 ↗
26. Influence of polyelectrolyte chemical structure on their interaction with lipid menbrane of Zwitterionic liposomes10.1021/bm800400y ↗
27. Chitosan-based multi-liposomal complexes: Synthesis, biodegradability and cytotoxicity10.1016/j.ijbiomac.2021.02.169 ↗
28. The membrane-activity of ibuprofen, diclofenac, and naproxen: A physico-chemical study with lecithin phospholipids10.1016/j.bbamem.2009.01.016 ↗
29. Physicochemical interaction study of non-steroidal anti-inflammatory drugs with dimyristoylphosphatidylethanolamine liposomes
30. Magnetic nanorods for remote disruption of lipid membranes by non-heating low frequency magnetic field10.1016/j.nano.2019.102065 ↗
31. Structure and stability of anionic liposomes complexes with PEG-chitosan branched copolymer10.1134/S1068162014050057 ↗
32. Maltoheptaose-presenting nanoscale glycoliposomes for the delivery of rifampicin to E. coli10.1021/acsanm.1c01320 ↗
33. The charge and phase state of liposomes dramatically affects the binding of Mannosylated chitosan10.3390/futurepharmacol2030023 ↗
34. Antibacterial activity of chitosan nanofiber meshes with liposomes immobilized releasing gentamicin10.1016/j.actbio.2015.02.018 ↗
35. Complexes of negatively charged liposomes with chitosan: Effect of phase state of the lipid bilayer10.1134/S1070363221100025X ↗
36. Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlusTM prediction studies10.1016/j.ejps.2020.105411 ↗
37. Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis10.3109/10837450.2015.1035728 ↗
38. β-Cyclodextrin hydrogels as potential drug delivery systems10.1016/j.carbpol.2011.10.024 ↗
39. Lattice self-assembly of cyclodextrin complexes and beyond10.1016/j.cocis.2019.01.002 ↗
40. A review on the recent development of cyclodextrin-based materials used in oilfield applications10.1016/j.carbpol.2020.116321 ↗
41. β-Cyclodextrin-functionalized hydrophobically associating acrylamide copolymer for enhanced oil recovery10.1021/ef302152t ↗
42. Alginate/chitosan nanoparticles for improved oral delivery of rifampicin: Optimization, characterization and in vitro evaluation10.14233/ajchem.2018.20904 ↗
43. Nano-vesicles of salbutamol sulphate in metered dose inhalers: Formulation, characterization and in vitro evaluation10.22159/ijap.2017v9i6.22448 ↗